Company
Novelty Nobility
Leadership
SAB
Contact Us
Platform
PREXISE-D
Pipeline
People
Culture
Careers
News
Careers
Publications
Blog
OTD Solution
Terms of Use
Private Policy
ddd
Company
Novelty Nobility
Leadership
SAB
Contact Us
Platform
PREXISE-D
Pipeline
People
Culture
Careers
News
Careers
Publications
Blog
OTD Solution
Terms of Use
Private Policy
PREXISE-D, Fit-for-Purpose
Antibody Design & Discovery
Learn more
Overcoming Drug Resistance
with Antibody-Drug Conjugate
Learn more
Bringing a Beautiful Moment of
Eye Contact to Everyone
Learn more
NEWS
[히트뉴스] 노벨티노빌리티, 233억 시리즈C 투자 유치… 내년 코스닥 상장 목표...
[PR Newswire] GC Biopharma and Novelty Nobility Enter into Joint Research and Development Agreement ...
[더바이오] GC녹십자-노벨티노빌리티, '지도모양위축증' 치료제 공동 연구개발 계약 체결...
[팜뉴스] 노벨티노빌리티, c-Kit 타깃 ADC “KDDF 과제 선정”
[한국경제] 노벨티노빌리티 후보물질 도입한 엑세러린… "재라이센싱 유력"...